NCT06315010 REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis Status RECRUITING Phase PHASE2
NCT06255951 Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects Status COMPLETED Phase PHASE1
NCT06248606 Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases Status RECRUITING Phase PHASE2
NCT06247280 Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR Mutation Status ACTIVE_NOT_RECRUITING Phase N/A
NCT06246110 A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC Status RECRUITING Phase PHASE2
NCT06221670 Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK) Status RECRUITING Phase PHASE2
NCT06218069 Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor Status NOT_YET_RECRUITING Phase PHASE2/PHASE3
NCT06207292 Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer Status RECRUITING Phase NA
NCT06182761 A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer Status NOT_YET_RECRUITING Phase PHASE2
NCT06142058 RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC Status RECRUITING Phase N/A
NCT06116019 Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS) Status RECRUITING Phase N/A
NCT06108726 A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer Status RECRUITING Phase PHASE2
NCT06107686 A Study of YL202 in Selected Patients With Advanced Solid Tumors Status RECRUITING Phase PHASE2
NCT06095934 Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI Treatment Status RECRUITING Phase NA
NCT06094296 A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) Status TERMINATED Phase PHASE2
NCT06090318 Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss Status WITHDRAWN Phase PHASE1/PHASE2
NCT06081777 Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer Status RECRUITING Phase N/A